Close Menu
The Central Wire
  • Home
  • News
  • Editorial
  • Business
  • Sci-Tech
  • Entertainment
  • Sports
  • Opinion
  • Markets
  • Automotive
  • Lifestyle
  • Tech Reviews
Facebook
The Central WireThe Central Wire
Subscribe
Thursday, June 5
  • Home
  • News
  • Editorial
  • Business
  • Sci-Tech
  • Entertainment
  • Sports
The Central Wire
  • Home
  • News
  • Editorial
  • Business
  • Sci-Tech
  • Entertainment
  • Sports
Home - Daily Science - Covaxin’s Intellectual Property Conundrum: Unveiling the Storm Behind Bharat Biotech’s Admission

Covaxin’s Intellectual Property Conundrum: Unveiling the Storm Behind Bharat Biotech’s Admission

Daily Science 30/06/2024Basanta Kumar SahooBy Basanta Kumar Sahoo3 Mins Read

A Seismic Shift in Vaccine Ownership: The Covaxin Intellectual Property Dispute

In a twist that has sent shockwaves through India’s scientific community, Bharat Biotech International Limited (BBIL), the esteemed maker of the indigenous COVID-19 vaccine Covaxin, has confessed to a grave omission in its patent filings. The biotech giant failed to acknowledge the pivotal role of Indian Council of Medical Research (ICMR) scientists as co-inventors, sparking a contentious debate over intellectual property rights (IPR).

Unraveling the Intricate Tapestry of Vaccine Patents

India’s patent laws, a complex labyrinth of product and process patents, grant inventors exclusive rights over their creations. While product patents safeguard the drug itself, process patents shield the intricate steps involved in its production. BBIL, in its patent filings, claimed ownership of the process of manufacturing Covaxin from virus strains provided by ICMR’s National Institute of Virology (NIV).

The NIV, renowned for its expertise in virus extraction, identification, and characterization, played a critical role in the vaccine’s development. However, transforming these viral strains into a viable vaccine on an industrial scale necessitates a sophisticated infrastructure only possessed by established vaccine manufacturers like BBIL.

The Intriguing Role of Adjuvants and the Race for Market Monopoly

Covaxin, an inactivated version of the COVID-19 virus, relies on an adjuvant to amplify its potency and stimulate a robust immune response. Vaccine manufacturers, driven by fierce competition, often develop proprietary adjuvants and guard their production processes zealously, seeking temporary market monopolies to reap the rewards of their innovation.

The ICMR-BBIL Alliance: A Partnership Fraught with Ambiguity

The collaboration between BBIL and ICMR-NIV, cemented by a formal agreement, delineated the responsibilities of each entity. ICMR, a public entity, not only provided the crucial virus strains but also conducted animal and human trials to assess the vaccine’s efficacy, investing a substantial ₹35 crore in the process. In return, ICMR was entitled to a 5% royalty on Covaxin sales.

The agreement, shrouded in secrecy until partially revealed in the Rajya Sabha in July 2021, fueled speculation that both entities would share joint intellectual property rights. However, BBIL initially asserted a distinction between manufacturing rights and rights over clinical trial data, excluding ICMR from patent applications.

The Unforeseen Admission: A Change of Heart Amidst Controversy

In a dramatic turn of events, BBIL, facing mounting public scrutiny, recanted its stance, admitting its error and pledging to rectify the patent filings by including ICMR personnel as inventors. The reasons behind this unexpected reversal remain shrouded in mystery.

The High Stakes of Inventorship: Unveiling the Implications

The omission of ICMR scientists as co-inventors in the patent filings carries profound implications. Inventorship plays a pivotal role in the allocation of intellectual property rights, royalties, and even the permissible uses of a product. In the intricate world of pharmaceutical development, where collaborations and licensing agreements are commonplace, the question of inventorship can make or break a company’s fortunes.

A Turning Point in Vaccine Development: Lessons Learned and the Path Forward

The Covaxin IPR dispute serves as a cautionary tale, highlighting the importance of transparency, collaboration, and meticulous attention to detail in the realm of scientific innovation. As India strives to become a global leader in vaccine development, it must foster an environment that encourages cooperation between public and private entities, ensuring that all contributors receive due recognition for their invaluable contributions.

Basanta Kumar Sahoo
Basanta Kumar Sahoo

Basant Kumar Sahoo is a seasoned writer with extensive experience in crafting tech-related articles, insightful editorials, and engaging sports content. With a deep understanding of technology trends, a knack for thought-provoking commentary, and a passion for sports, Basant brings a unique blend of expertise and creativity to his writing. His work is known for its clarity, depth, and ability to connect with readers across diverse topics.

Bharat Biotech Covaxin COVID-19 ICMR intellectual property rights patent filings vaccine development
Previous ArticleLife-Saving Armor: inStem’s Anti-Insecticide Fabric Revolutionizes Farmer Protection
Next Article Dengue’s Enigma: A Surprising Shield Against COVID’s Onslaught?

Keep Reading

Asteroid 2024 PT5 Becomes Earth’s Mini-Moon for 56 Days

New Antibody SC27 Targets Covid Variants with Breakthrough Potency

Battle Against Asian Hornets: An Urgent Mission to Protect the UK’s Ecosystem

DMCA.com Protection Status
World At a Glance

Ireland Hate Speech Law Shelved After Controversy

22/09/2024

Russian Airstrike Hits Kharkiv, Injuring 12 Civilians

22/09/2024

Ukraine War: Russia Rejects Peace Talks in Diplomatic Blow

22/09/2024

France Right-Wing Government Rises Amid Political Deadlock

22/09/2024

Ukraine War: Allies’ Support Key to Victory, Zelenskyy Warns

22/09/2024
Trending Now

Armani/Caffè Debuts in Mumbai, Redefining Luxury Dining

13/09/2024

Friday the 13th: Superstition, History, and the Internet’s Obsession

13/09/2024

Paris Paralympics 2024: India’s Record 29 Medals Achieved

09/09/2024

All the Winners (and EGOTs) of the 2024 Creative Arts Emmys

09/09/2024

Gillian Anderson’s Evolution: From Iconic TV Star to Advocate for Women’s Sexual Liberation

09/09/2024
TCW LOGO
  • World Today
  • India Today
  • Sports
  • Entertainment
  • Business
  • Gadgets Review
  • Car Review
  • Bike Review
  • Mobile Review
  • Tablet review
  • Editorials
  • Opinion
  • Editor's Choice
  • Explained
  • Trending Now
© 2025 The Central Wire or its affiliated companies. All rights reserved.
  • Privacy Policy
  • Terms
  • About Us
  • Contact Us

Type above and press Enter to search. Press Esc to cancel.